CHF91.08
0.10% today
SIX Swiss Exchange, Nov 21, 09:43 am CET
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Novartis Stock price

CHF90.99
-9.45 9.41% 1M
-2.38 2.55% 6M
+6.12 7.21% YTD
+6.71 7.96% 1Y
+19.69 27.61% 3Y
+6.90 8.20% 5Y
+15.30 20.21% 10Y
SIX Swiss Exchange, Closing price Wed, Nov 20 2024
-0.07 0.08%
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Key metrics

Market capitalization CHF178.02b
Enterprise Value CHF193.43b
P/E (TTM) P/E ratio 11.91
EV/FCF (TTM) EV/FCF 14.93
EV/Sales (TTM) EV/Sales 4.51
P/S ratio (TTM) P/S ratio 4.15
P/B ratio (TTM) P/B ratio 4.98
Dividend yield 3.63%
Last dividend (FY23) CHF3.30
Revenue growth (TTM) Revenue growth -8.46%
Revenue (TTM) Revenue CHF42.90b
EBIT (operating result TTM) EBIT CHF12.71b
Free Cash Flow (TTM) Free Cash Flow CHF12.95b
Cash position CHF11.83b
EPS (TTM) EPS CHF7.64
P/E forward 18.36
P/S forward 3.97
EV/Sales forward 4.31
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Analyst Opinions

26 Analysts have issued a Novartis forecast:

5x Buy
19%
19x Hold
73%
2x Sell
8%

Analyst Opinions

26 Analysts have issued a Novartis forecast:

Buy
19%
Hold
73%
Sell
8%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
42,905 42,905
8% 8%
100%
- Direct Costs 11,229 11,229
20% 20%
26%
31,675 31,675
3% 3%
74%
- Selling and Administrative Expenses 5,739 5,739
22% 22%
13%
- Research and Development Expense 7,917 7,917
1% 1%
18%
18,020 18,020
10% 10%
42%
- Depreciation and Amortization 5,311 5,311
35% 35%
12%
EBIT (Operating Income) EBIT 12,708 12,708
6% 6%
30%
Net Profit 15,573 15,573
117% 117%
36%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

AD HOC NEWS
about 10 hours ago
Der Schweizer Pharmakonzern Novartis CH0012005267 rechnet sich nach seinem Umbau mittelfristig noch etwas mehr Wachstum aus als bisher.
AD HOC NEWS
about 10 hours ago
Die Aktien von Novartis CH0012005267 dürften am Mittwoch mit Gewinnen in den Handel starten.
AD HOC NEWS
23 days ago
Der Schweizer Pharmakonzern Novartis CH0012005267 hat zum dritten Mal in diesem Jahr seine Jahresprognose erhöht.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today